282 Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy

282 Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy

Bibliographic Details
Main Authors:	Jared Lunceford, Lingkang Huang, Junshui Ma, Kenneth Emancipator
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
by: Hao‐Chun Chang, et al.
Published: (2020-08-01)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
by: Mitsunori Morita, et al.
Published: (2020-02-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
by: Bernard F. Hearon, et al.
Published: (2020-12-01)

81 Inclusion of PD-L1-expressing tumor cells in the combined positive score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications
by: Jonathan Juco, et al.
Published: (2020-11-01)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
by: N.Y.L. Ngoi, et al.
Published: (2018-05-01)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
by: Taisuke Isono, et al.
Published: (2021-05-01)

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
by: Yu Zhang, et al.
Published: (2021-03-01)

The Three P’s: Parotid, PD-L1, and Pembrolizumab
by: Amanda Wiggins, et al.
Published: (2019-01-01)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)

373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
by: Yan Wang, et al.
Published: (2020-11-01)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
by: Nora Möhn, et al.
Published: (2021-03-01)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
by: Albright, A., et al.
Published: (2022)

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
by: S. Y. Cindy Yang, et al.
Published: (2021-08-01)

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
by: Kazutaka Hosoya, et al.
Published: (2021-04-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Immunogenicity of pembrolizumab in patients with advanced tumors
by: Marianne J. H. van Vugt, et al.
Published: (2019-08-01)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
by: Aaron S. Mansfield, MD, et al.
Published: (2021-08-01)

Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients
by: Hyun Ju Kim, et al.
Published: (2019-09-01)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
by: Bernhard Roither, et al.
Published: (2021-12-01)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
by: Lyu M, et al.
Published: (2020-05-01)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
by: Ya Chen, et al.
Published: (2021-06-01)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
by: Noguchi S, et al.
Published: (2020-07-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Editorial 28.2
by: Hormindo Pereira de Souza Junior, et al.
Published: (2019-09-01)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
by: Hanno M. Witte, et al.
Published: (2020-04-01)

Advanced G‐CSF‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy
by: Yohei Matsui, et al.
Published: (2020-10-01)

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-10-01)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
by: Valerie Glutsch, et al.
Published: (2019-07-01)

Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report
by: Naoyuki Okabe, et al.
Published: (2021-04-01)

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types
by: Gangadhar TC, et al.
Published: (2015-04-01)

261 Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180
by: Takashi Kojima, et al.
Published: (2020-11-01)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
by: Zuan Lin
Published: (2019-03-01)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
by: Elan Gorshein, et al.
Published: (2021-06-01)

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
by: Elisabeth G E de Vries, et al.
Published: (2020-07-01)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
by: Gagandeep Brar, et al.
Published: (2019-08-01)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
by: Xiong F, et al.
Published: (2020-07-01)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
by: Tozuka T, et al.
Published: (2018-09-01)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
by: Anissa Roger, et al.
Published: (2018-07-01)

Cannot write session to /tmp/vufind_sessions/sess_n2lj2ufgbmuffpi1fpj37j1t3i